Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy
Patients receiving extended cycles of PRRT showed improved survival outcomes in metastatic PanNET, particularly in patients with lower tumor grades and without bone metastases. No survival difference was seen between functioning and non-functioning PanNET, while patients with grade 3 tumors and bone metastases had significantly shorter survival despite PRRT.
Authors
- Johanna Braegelmann (ORCID: https://orcid.org/0009-0006-8696-8291)
- Harald Lahner (ORCID: https://orcid.org/0009-0008-0843-1565)
- David Kersting (ORCID: https://orcid.org/0000-0002-8451-1830)
- Wolfgang P. Fendler (ORCID: https://orcid.org/0000-0002-5106-3584)
- Annie Mathew (ORCID: https://orcid.org/0000-0003-3233-5609)
- Dagmar Führer
Institutions
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-04-15
- DOI
- https://doi.org/10.3389/fendo.2025.1526470
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Universität Duisburg-Essen